Patients with an established diagnosis of diabetes or admission blood glucose levels of >11 mmol/L with or without a history of diabetes, and a diagnosis of MI in the previous 24 h were included in the trial and randomly assigned to receive insulin‐glucose infusion at admission followed by 3‐months insulin therapy or conventional therapy (Malmberg et al., 1995). The gene discussed is INS; the disease is diabetes mellitus.